Severe Plasmodium knowlesi Malaria in a Tertiary
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The simian parasite Plasmodium knowlesi causes 
severe human malaria; the optimal treatment remains 
unknown. We describe the clinical features, disease 
spectrum, and response to antimalarial chemotherapy, 
including artemether-lumefantrine and artesunate, in 
patients with P. knowlesi malaria diagnosed by PCR during 
December 2007–November 2009 at a tertiary care hospital 
in Sabah, Malaysia. Fifty-six patients had PCR-conﬁ  rmed 
P. knowlesi monoinfection and clinical records available for 
review. Twenty-two (39%) had severe malaria; of these, 
6 (27%) died. Thirteen (59%) had respiratory distress; 12 
(55%), acute renal failure; and 12, shock. None experienced 
coma. Patients with uncomplicated disease received 
chloroquine, quinine, or artemether-lumefantrine, and 
those with severe disease received intravenous quinine or 
artesunate. Parasite clearance times were 1–2 days shorter 
with either artemether-lumefantrine or artesunate treatment. 
P. knowlesi is a major cause of severe and fatal malaria 
in Sabah. Artemisinin derivatives rapidly clear parasitemia 
and are efﬁ  cacious in treating uncomplicated and severe 
knowlesi malaria.
T
he simian parasite Plasmodium knowlesi has recently 
been found to be a major cause of human malaria in 
Malaysian Borneo (1,2), with the disease also reported 
from southern and eastern Asia (3). To our knowledge, 
the only large epidemiologic and clinical studies have 
been from Sarawak State, Malaysian Borneo, with case 
series or reports from persons or returning travelers from 
Myanmar (4), Thailand (5,6), Vietnam (7), Philippines 
(8,9), Singapore (10), Sarawak (11), western Malaysia 
(12), and Indonesia (13).
The potential for P. knowlesi to cause severe disease 
has been suggested by experimental simian and human 
infections (14–16). The ﬁ   rst description of naturally 
acquired severe human P. knowlesi infection was a 
retrospective study from Sarawak that detailed 4 fatal cases 
with multiorgan failure (17). Subsequently, a prospective 
study from the Kapit District Hospital in Sarawak 
enrolled 107 persons with P. knowlesi monoinfection and 
demonstrated that 10 patients had severe disease as deﬁ  ned 
by World Health Organization (WHO) criteria, resulting in 
2 deaths (2).
The disease spectrum and clinical features of large 
numbers of patients infected with P. knowlesi have not 
been described outside Sarawak. To reliably differentiate 
P. malariae from P. knowlesi infections by using only 
microscopy is difﬁ  cult (18); such differentiation requires 
molecular methods (1). In a random survey from several 
districts in Sabah, the state that borders Sarawak, 44 of 
49 cases of microscopy-diagnosed P. malariae infection 
were conﬁ  rmed by PCR to be P. knowlesi, indicating that 
knowlesi malaria was not conﬁ  ned to isolated areas (17). In 
recent years at Queen Elizabeth Hospital (QEH), a tertiary 
care referral hospital in Kota Kinabalu, Sabah State, 
patients with severe malaria by WHO criteria had received 
a diagnosis by microscopy as P. malariae infection, but 
P. knowlesi was suspected as the etiologic agent. We 
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conducted a retrospective review of the clinical spectrum 
of all case-patients with P. malariae malaria who were 
admitted to QEH during December 2007–November 2009 
and conﬁ  rmed the diagnosis of P. malariae or P. knowlesi 
infection by molecular methods.
The optimal management of knowlesi malaria is 
not known. P. knowlesi infection has been successfully 
treated with chloroquine (2) and quinine (2); however, 
the therapeutic efﬁ   cacy of other antimalarial agents is 
not known. Artemisinin-derivative combination therapy 
is now the WHO treatment of choice for uncomplicated 
falciparum malaria (19) and is increasingly recommended 
for nonfalciparum malaria (20); its efﬁ  cacy in knowlesi 
malaria is unknown. Similarly, intravenous artesunate is 
now the treatment of choice for severe falciparum malaria 
in adults (19,21), but the therapeutic response to this 
regimen in severe knowlesi malaria is unknown. As part 
of our study, we documented the therapeutic responses in 
uncomplicated and severe knowlesi malaria treated with 
artemisinin derivatives.
Methods
Study Site
QEH serves as a tertiary care hospital for the Malaysian 
state of Sabah, which has an estimated population of 3 
million. It has a modern well-equipped intensive care 
unit with facilities for invasive ventilation, hemodynamic 
support, and renal replacement therapy.
Retrospective Case Review
All patients with microscopy-diagnosed malaria during 
December 2007–November 2009 were recorded from a 
prospective laboratory register, and those with P. malariae 
monoinfection or mixed infections were identiﬁ  ed. 
Additional patients, for whom conditions had been 
diagnosed by microscopy as caused by other Plasmodium 
species but were identiﬁ  ed as P. knowlesi infections by 
PCR, were also included. Case records were reviewed, and 
clinical information was entered into a standardized data 
collection form. Severe disease was classiﬁ  ed on the basis of 
WHO criteria for severe falciparum malaria (22). National 
policy recommends that all patients with microscopy-
diagnosed malaria be hospitalized until negative blood 
smears are obtained on 2 consecutive examinations. The 
study was approved by the Medical Research Ethics Sub-
Committee of the Malaysian Ministry of Health and the 
Menzies School of Health Research, Australia.
Laboratory Procedures
Blood ﬁ  lms were examined by experienced laboratory 
microscopists, and the parasite count was classiﬁ  ed on a 
scale of 1 to 4 (1= 4–40 parasites/μL, 2 = 41–400 parasites/
μL, 3 = 401–4,000 parasites/μL, 4 = >4,000 parasites/μL). 
Hematologic results (Sysmex XT1800 [Sysmex Corp., 
Mundelein, IL, USA] and CELL-DYN Sapphire [Abbott 
Diagnostics, Abbot Park, IL, USA]) and prothrombin and 
partial thromboplastin times (STA Compact Hemostasis 
Analyzer [Diagnostica Stago, Asnières sur Seine, France]) 
were obtained on site. Serum sodium, potassium, glucose, 
creatinine, bilirubin, albumin (Roche/Hitachi Modular 
Analytics EVO, Roche, Basel, Switzerland), and arterial 
blood gas levels (Radiometer ABL520, Radiometer, 
Brønchøj, Denmark) were also assayed on site. Blood 
cultures were performed with an automated system (Becton 
Dickinson, Franklin Lakes, NJ, USA) and dengue serology 
by ELISA (PanBio, Brisbane, Australia). In accordance with 
QEH policy, all slides indicating P. malariae monoinfection 
or mixed infections were sent for molecular testing at the 
Sabah State Reference Laboratory, along with ≈15% of other 
species. Parasite DNA was extracted, and nested PCR was 
performed for P. falciparum, P. vivax, P. malariae, P. ovale, 
and P. knowlesi by methods previously published (1,17).
Statistical Analysis
Data were analyzed by using STATA version 9.2 
(StataCorp LP, College Station, TX, USA). For continuous 
variables, intergroup differences were compared by Student 
t test or Mann-Whitney U test. For categorical outcome 
variables, intergroup differences were compared by using 
the χ2 test or Fisher exact test. Logistic regression was used 
to determine the association between binary outcomes and 
other variables. A 2-sided value of p<0.05 was considered 
signiﬁ  cant.
Results
Baseline Characteristics
Included in the ﬁ  nal analysis were 56 patients with 
PCR-conﬁ  rmed  P. knowlesi malaria. On the basis of 
WHO severity criteria (22), 22 (39%) had severe malaria, 
and 34 (61%) had uncomplicated disease (Figure). These 
patients were identiﬁ  ed from a group of 74 patients with 
documented P. malariae malaria listed in the laboratory 
microscopy register: 54 had P. knowlesi monoinfection 
shown by PCR and medical records available for review 
(Figure). In addition, another 2 patients received a diagnosis 
by microscopy as being infected with other Plasmodium sp. 
but were found to have P. knowlesi monoinfections on PCR 
testing (Figure). All 24 patients with severe malaria had 
PCR performed; of these, 22 had P. knowlesi monoinfection 
(Figure). In the group with uncomplicated infection, 41 
had PCR; 34/41 had only P. knowlesi monofection; 4 
cases were mixed with P. knowlesi and other species; 2 
cases were non–P. knowlesi, and no Plasmodium sp. was 
detected in 1 patient (Figure).
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The baseline demographics and clinical symptoms 
of both groups with PCR-conﬁ  rmed  P. knowlesi 
monoinfections are detailed in Table 1. The mean age of 
the patients with severe malaria (57 years; 95% conﬁ  dence 
interval [CI] 50–64 years) was signiﬁ   cantly older than 
that of the uncomplicated group (37 years; 95% CI 34–42 
years) (p<0.001); however, the proportion with chronic 
coexisting conditions did not differ signiﬁ  cantly between 
groups (Table 1). In severe disease, the proportion of 
female patients (36%) was signiﬁ  cantly higher than that in 
uncomplicated malaria (8.8%) (odds ratio [OR] 5.9, 95% 
CI 1.4–25.6; p = 0.02). Overall, 8 of 11 female patients 
had severe disease. Two women were pregnant; 1 had 
severe malaria, and the other had uncomplicated malaria. 
Two male patients had second uncomplicated infections 
during the study period; 1 became infected 10 months after 
the ﬁ  rst, and the other had a mixed P. vivax/P. knowlesi 
infection 6 weeks after initial infection. Both patients had 
received chloroquine for the ﬁ  rst P. knowlesi infection. One 
patient with uncomplicated disease also had HIV infection.
Almost all patients with severe and uncomplicated 
disease had a history of fever, and no signiﬁ  cant difference 
was found in duration of fever or other clinical symptoms 
before the patient sought treatment (Table 1). However, 
patients with severe complications had a lower mean 
arterial pressure and an increased respiratory rate. Of 
those not already intubated on transfer or admission to 
QEH, patients with severe disease also had lower oxygen 
saturation at room air than did those with uncomplicated 
disease (Table 1).
Laboratory and Radiologic Investigations
In patients with severe disease, hemoglobin 
concentrations and platelet counts were signiﬁ  cantly 
lower, and leukocyte counts, prothrombin time, and 
partial thromboplastin time were elevated, compared with 
results for patients with uncomplicated malaria (Table 2). 
Sodium and albumin concentrations were also signiﬁ  cantly 
decreased, and creatinine and total bilirubin levels increased 
in patients with severe disease (Table 2). Parasite counts 
were signiﬁ  cantly higher in severe disease (Table 2). Blood 
cultures, performed in 12/34 patients with uncomplicated 
disease, were all negative. Dengue serologic testing was 
performed on admission for 11 patients with uncomplicated 
disease; 10 were negative for immunoglobulin (Ig) M and 
IgG, and 1 patient was positive for IgM. Blood cultures 
were performed for 17 patients with severe disease; 
1 patient had Enterobacter cloacae bacteremia, 5 had 
coagulase-negative  Staphylococcus infection (attributed 
to contamination), and samples from the remainder were 
negative. Dengue serologic tests for 10 patients with severe 
disease were all negative. Chest radiographs were obtained 
on admission for 30 patients (8 with uncomplicated disease, 
17 with severe disease); none with uncomplicated disease 
were reported to have inﬁ  ltrates, compared with 8/17 with 
severe disease (p = 0.01); all of those with severe disease 
had acute respiratory distress syndrome (ARDS) with 
hypoxemia.
Severe Malaria
Of patients with severe disease, 17 were referred from 
district hospitals and 5 were directly admitted. Twenty-
one of these patients had complications on admission, and 
in 1 patient with acute renal failure, respiratory distress 
developed 3 days after the start of therapy. During the 
hospital course, 7 patients each had 1 WHO criterion for 
severity, and 15 each had >2 severity criteria (2, n = 6; 
3, n = 5; 4, n = 1; 5, n = 1; and 6, n = 2) (Table 3). The 
mean age of the 6 patients who died was 64 years (95% CI 
49–78 years), and the mean age of the 16 survivors (was 53 
years (95% CI 45–61 years; p = 0.1). Decreased Glasgow 
Coma Scores (GCS 14 and 11) on initial hospital visit were 
seen in 2 patients who died, but other signs and symptoms 
did not satisfy WHO criteria for cerebral malaria. No cases 
of severe anemia (<6 g/dL) were found. Acute respiratory 
distress (n = 13), acute renal failure (n = 12), shock (n = 
12), and hyperbilirubinemia (n = 9) were the most common 
manifestation of severe disease (Table 3). Seven patients 
had acidosis (on the basis of arterial blood gas analysis) 
(Table 3). Seven (32%) patients had signiﬁ  cant elevations 
of the prothrombin and partial thromboplastin times, 
although none were reported to have clinically important 
bleeding. In patients with acute respiratory distress, the ratio 
of the partial pressure of oxygen to the fraction of inspired 
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Figure. Flowchart of microscopy and PCR results of Plasmodium 
malariae or P. knowlesi infections by severity, Sabah, Malaysia, 
2007–2009.Severe P. knowlesi Malaria
oxygen (PaO2:FiO2) was available for 11/13 patients. In 
this group, the mean ratio was 165 (range 101–250), with 
10 meeting the criteria for ARDS (PaO2:FiO2 <200). Eight 
patients had cardiac function evaluated by transthoracic 
echocardiogram, and all had normal results, except for a 
76-year-old woman with a left ventricular ejection fraction 
of 30%.
Seventeen patients required intensive care unit 
management, 12 received inotrope support, 11 required 
hemodialysis, and 10 received mechanical ventilation 
(Table 3). The median duration of intensive care stay was 
6 days (range 1–11 days); for hemodialysis, 3 days (range 
1–6); and for mechanical ventilation, 3 days (range 1–9). 
Eleven patients were transfused with erythrocytes, 2 with 
fresh frozen plasma, and 4 with platelets (Table 3).
Malarial and Antimicrobial Drug Therapy
Of 34 patients with conﬁ  rmed,  uncomplicated  P. 
knowlesi malaria, 15 received oral chloroquine, 11 received 
oral quinine, and 8 received artemether-lumefantrine. Two 
patients from the quinine group received intravenous 
quinine for ≈24 hours before treatment was changed to 
oral therapy. Daily peripheral blood ﬁ  lms were available 
for 10 patients who received chloroquine (mean admission 
parasitemia 2+), for 8 who received quinine (mean 
admission parasitemia 3+), and for 6 who received 
artemether-lumefantrine (mean admission parasitemia 
2+). When we excluded patients who received intravenous 
therapy initially, the difference was signiﬁ  cant in median 
parasite clearance times between those who received 
artemether-lumefantrine (1 day; range 0–3) and those who 
received chloroquine (2.5 days; range 1–3) or quinine (2.5 
days; range 1–3); p = 0.01. The proportion with negative 
results for parasitemia by day 1 was 4/6, 3/10, and 1/8 
for artemether-lumefantrine, chloroquine, and quinine, 
respectively (p = 0.1), and 5/6, 5/10, and 4/8 for each group 
on day 2 (p = 0.2). Among patients with uncomplicated 
disease, 11/34 patients received doxycycline, and 
7/34 received other antimicrobial drugs during their 
hospitalization.
In December 2008, hospital policy changed, and 
the recommendation was made that patients receive 
intravenous artesunate, when available, rather than quinine 
for treatment of severe malaria. Of the 22 patients with 
severe  P. knowlesi malaria, 16 received intravenous 
quinine, and 6 received intravenous artesunate. Daily 
peripheral blood ﬁ  lms were available for 11 of the patients 
in the quinine group (mean admission parasitemia 3+) 
and 4 of the artesunate group patients (mean admission 
parasitemia 3+), with median parasite clearance time 
signiﬁ  cantly shorter with artesunate (2 days; range 1–3) 
than with quinine (4 days; range 2–7) (p = 0.02). Of the 
6 patients who died, 5 received quinine (median severity 
criteria 2; case-fatality rate 31%), and 1 received artesunate 
(median severity criteria 2.5; case-fatality rate 16.6%). Of 
patients with severe malaria, 13/22 received doxycycline, 
and 16/22 received other antimicrobial drugs during their 
hospital course.
Outcome
Six (27%) of the 22 patients with severe malaria died; 
mean time from admission to QEH and death was 2.5 days 
(range 0–4). Of these, all had >3 severity criteria; 6 had 
ARDS, 5 had acute renal failure, and 4 had shock. All 
patients who died had a parasitemia level of 4+; survivors 
had a median level of 3+. None of the patients with 
uncomplicated disease died. The mean duration of hospital 
stay was 8.4 days (95% CI 6.3–10.5) for those with severe 
disease and 5.3 days (95% CI 4.1–7.4) for those with 
uncomplicated malaria.
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Table 1. Baseline demographic characteristics and clinical features of patients with severe and uncomplicated Plasmodium knowlesi 
malaria, Sabah, Malaysia, 2007–2009  
Characteristic Uncomplicated disease, n = 34  Severe disease, n = 22 
Mean age, y* (range)  37 (20–66)  57 (22–84) 
No. (%) female patients†  3 (8.8)  8 (36.3) 
Self-reported previous malaria, no. patients  1 0
History of chronic illness, %  18 10
Mean duration of illness, d (range)  5.0 (1–30)  5.2 (2–7) 
Symptoms 
 Fever,  %  100 96
 Headache,  %  62 57
 Diarrhea,  %  21 24
Physical findings 
  Mean temperature (range)  38.2°C (36.5–41°C)  37.6°C (36.7–39.2°C) 
  Mean respiratory rate, breaths/min* (range)  20 (14–26)  26 (15–50) 
  Mean pulse rate, beats/min (range)  95 (69–151)  100 (76–130) 
  Mean arterial pressure, mm Hg (range)*  85 (61–106)  74 (42–106) 
  Mean oxygen saturation, % (range)*  98 (92–100), n = 20  88 (56–100), n = 17 
*p<0.05 by Mann Whitney U test. 
†p<0.05 by Ȥ
2 test. RESEARCH
Discussion
Studies from Sarawak have shown that P. knowlesi 
infections can result in severe and fatal disease (2,17). The 
present 2-year case series from Sabah indicates that in a 
tertiary referral hospital setting, the proportion of severe 
P. knowlesi malaria is higher than reported previously, 
with 39% of patients having severe malaria according to 
WHO criteria. The increased frequency of severe disease 
likely reﬂ  ects referral bias because a large proportion of 
patients were referred from surrounding district hospitals. 
The case-fatality rate for severe malaria of 27% in this 
study is comparable to that of a previous study (2) and at 
least as high as that seen with P. falciparum malaria (21). 
The main demographic factors for severe malaria were 
increasing age (mean 57 years) and female gender. The 
former is consistent with a study of falciparum malaria 
where age was an independent risk factor for development 
of severe disease and death (23). The reason(s) for the 
large proportion of severe disease in female patients, noted 
previously in knowlesi malaria (2) and vivax malaria (24), 
remain unclear.
For 12 of the 13 patients with respiratory distress, the 
diagnosis was conﬁ  rmed by a low arterial partial pressure 
of oxygen and decreased oxygen saturation with a need 
for mechanical ventilation. One patient with an increased 
respiratory rate alone had metabolic acidosis; the 4 other 
patients had ARDS and hypoxemia. This ﬁ  nding suggests 
that hypoxemia from acute lung injury is the major cause 
of respiratory distress in P. knowlesi malaria, although 
metabolic acidosis can also contribute. Shock occurred 
in more than half of patients who had severe malaria; 
however, repeated blood cultures showed clinically 
signiﬁ  cant bacteremia in <10% of patients, which suggests 
that in most cases of severe knowlesi malaria, concurrent 
bacteremia does not contribute to hypotension. A previous 
report with smaller numbers of severe knowlesi malaria 
found metabolic acidosis in only 10% (2), compared with 
30% of severe patients in this study for whom arterial 
blood gas results showed clear metabolic acidosis. The 
cause in 6 of 7 patients with acidosis may have been shock 
and hypoxemia; only 1 patient had neither. Although 30% 
of patients with severe disease had elevated prothrombin 
time or partial thromboplastin time, no clinically notable 
bleeding episodes were observed.
The susceptibility of pregnant women to severe disease 
in falciparum malaria (22) may also be the case in knowlesi 
malaria; 18% of women admitted with P. knowlesi malaria 
were pregnant. One patient in the third trimester of 
pregnancy survived acute renal failure and shock, but the 
fetus died.
The multiorgan failure experienced by patients with 
severe knowlesi malaria is similar to that reported in 
adults with severe falciparum malaria in areas where the 
transmission rate is low and unstable (22). However, as 
seen in a smaller series of severe knowlesi malaria, the 
≈50% proportion with ARDS and shock is higher than that 
reported in series of severe falciparum malaria (22,23,25–
29). Furthermore, 2 of the major clinical syndromes 
of severe falciparum malaria—unarousable coma and 
severe anemia—were absent (2). The absence of severe 
anemia may reﬂ  ect the lower malaria transmission rate, 
the relatively short duration of illness, and the exclusion 
from this adult referral hospital of children, an age group 
prone to this complication in falciparum malaria (23). 
Severe anemia has been described in knowlesi malaria 
in children elsewhere in Sabah (30). The reasons for the 
lack of coma are less clear and may reﬂ  ect differences in 
pathophysiology between knowlesi and falciparum malaria. 
In the only detailed autopsy study of fatal knowlesi malaria, 
widespread microvascular parasite accumulation was 
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Table 2. Laboratory results for patients with severe and uncomplicated Plasmodium knowlesi malaria, Sabah, Malaysia, 2007–2009* 
Laboratory result  Uncomplicated disease, n = 34  Severe disease, n = 22 
Parasite count†  3 (1–4)  4 (2–4) 
Hemoglobin concentration, gm/dL†  13.4 (9.1–17.6)  11.3 (6.2–16.8) 
Leukocyte count, u 10
3 cells/μL†  6.3 (3.4–15.3)  12.7 (3.5–21.6) 
Neutrophil count, u 10
3 cells/μL†  3.9 (1.4–10.1)  9.0 (2.73–16.9) 
Lymphocyte count u 10
3 cells/μL†  1.6 (0.6–3.3)  2.3 (0.24–6.4) 
Prothrombin time, s†  13.8 (10.6–17.5)‡   14.9 (11.7–21)§ 
Partial thromboplastin time, s†  40 (29.9–57.6)‡   57 (31–136)§  
Platelet count u 10
3 cells/μL†  72 (21–227)  40 (12–130) 
Serum creatinine, μmol/L†  92.6 (57–168)  289 (53–819) 
Serum sodium concentration, mmol/L†  136 (128–146)  131 (123–140) 
Serum total bilirubin, μmol/L  25.2 (4–48)¶   173 (11–660) 
Serum albumin, gm/dL†  38 (26–73)#   22 (18–27) 
*All values are mean (range). 
†p<0.05 by Student t test or Mann Whitney U test. 
‡n = 23. 
§n = 19. 
¶n = 15. 
#n = 13. Severe P. knowlesi Malaria
found, including within the brain, but no features to suggest 
cytoadherence of parasitized red cells to endothelial cells, 
a hallmark of the pathophysiology of severe falciparum 
malaria (31). Additional causes of impaired microvascular 
ﬂ  ow and organ dysfunction in falciparum malaria include 
dysregulated immune responses (32), endothelial activation 
with elevated angiopoietin-2 and von Willebrand factor 
(33,34), and decreased vascular nitric oxide bioavailability 
(25) and red cell deformability (35), but their roles in 
knowlesi malaria remain unknown.
Thrombocytopenia is nearly universal in P. knowlesi 
infections; platelet counts are lowest in cases of severe 
disease when no evidence suggests concurrent dengue. In 
contrast to platelet counts, leukocyte counts were higher in 
severe malaria than in uncomplicated malaria. Secondary 
bacterial infection was uncommon, which suggests that 
severe  P. knowlesi infection itself may account for the 
neutrophilia.
The optimal management of knowlesi malaria is not 
known, and the 2010 WHO Malaria Treatment Guidelines 
do not provide recommendations for its treatment 
(19). Artemisinin-derivative combination therapy is 
recommended as ﬁ  rst-line treatment of falciparum malaria 
in Africa and Asia, but there are no reports of artemisinin-
derivative combination therapy efﬁ  cacy in knowlesi malaria. 
In previous reports, uncomplicated P. knowlesi malaria was 
treated with chloroquine and primaquine (2,36), whereas 
severe disease was treated with intravenous quinine 
(1,2,17). Past studies in Sarawak have shown that although 
most patients with microscopy-diagnosed P. malariae 
infection had P. knowlesi, ≈10% were actually infected with 
P. falciparum (17). In settings such as Malaysia, with a high 
prevalence of chloroquine-resistant falciparum malaria 
(37,38), inadvertent use of chloroquine for misdiagnosed 
falciparum malaria may have deleterious consequences. 
In uncomplicated knowlesi malaria, we found that 
chloroquine, quinine, and artemether-lumefantrine were all 
efﬁ  cacious, and although comparisons were uncontrolled, 
those receiving artemether-lumefantrine had faster parasite 
clearance times. The 1-day median parasite clearance time 
after using artemether-lumefantrine in our hospitalized 
patients was similar to that seen in a community study in 
which chloroquine was used (2), though parasite densities 
may not have been comparable.
Intravenous artesunate (compared with quinine) 
reduces the proportion of deaths in severe falciparum 
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Table 3. Details of patients with severe Plasmodium knowlesi malaria, Sabah, Malaysia, 2007–2009* 
Patient no. 
Age, y/ 
sex Severity† 
Parasite
count
Platelets/
μL
Blood
products ICU Inotropes Ventilation Dialysis Treatment Outcome
P. knowlesi only
  1  76/M 1, 6, 7  3 17,000  Plt Y N N N Artesunate  S
 2  22/M 4,  7  3 38,000  Bld Y Y Y N Quinine  S
 3  29/M 2 4 16,000  Bld,  Plt  Y N Y Y Quinine  S
  4  76/F  1, 2, 3, 4, 
6, 7 
4 42,000 Bld Y Y Y Y Quinine  D
 5  50/M 2,  4  2 60,000  Bld Y Y N Y Quinine  S
  6  55/M 2, 4, 7  4 42,000  N Y Y N N Quinine  S
 7  49/M 1 4 78,000  N Y N N N Quinine  S
 8  38/F  2 4 29,000  Bld Y N N Y Quinine  S
 9  65/M 3,  4  3 17,000  N N N N N Quinine  S
  10  70/F  2, 4, 6, 7  4 48,000  Bld Y Y Y Y Quinine  S
  11  65/F  1, 2, 4, 6, 
7
4 26,000 Bld,  FFP Y Y Y Y Quinine  D
 12  75/F  4, 6  3 22,000  N N Y N N Artesunate  S
 13  69/F  7 2 130,000  N N N N N Artesunate  S
  14  57/M 1, 2, 3, 4, 
6, 7 
4 35,000 Bld,  Plt, 
FFP 
Y Y Y Y Artesunate D
 15  60/M 1 4 37,000  N N N N N Quinine  S
 16  44/M 1 3 61,000  N N N N N Artesunate  S
 17  54/M 4,  7  2 72,000  N Y Y N N Quinine  S
 18  69/M 1,  2  3 41,000  Bld Y N N Y Quinine  S
  19  84/F  2, 5, 7  2 34,000  N N N Y N Quinine  D
  20  54/F  2, 4, 7  3 12,000  Bld, Plt  Y Y Y Y Artesunate  S
 21  56/M 4,  7  4 28,000  N N Y Y N Quinine  D
  22  46/M 1, 2, 7  4 16,000  N Y Y Y Y Quinine  D
P. vivax + 
P. knowlesi
48/M 1, 2, 6  2 24,000 N Y N N Y Artesunate  S
ND 28/M 7 3 80,000  N Y N Y N Artesunate  S
*ICU, intensive care unit; Bld, blood; Plt, platelets; Y, yes; N, no; S, survived; D, died; FFP, fresh frozen plasma; ND, none detected. 
†Severity criteria: 1, hyperbilirubinemia; 2, acute renal failure; 3, hypoglycemia; 4, shock; 5, blackwater fever; 6, acidosis; 7, respiratory distress. RESEARCH
malaria (21), but its efﬁ  cacy is unknown in severe knowlesi 
malaria. In our study, artesunate-treated patients had faster 
parasite clearance, and the case-fatality rate (17%) was 
lower than for those who received quinine (31%). However, 
the retrospective design and small number of severe cases 
and deaths do not enable us to assess a possible survival 
beneﬁ  t. Current treatment policy at QEH for uncomplicated 
knowlesi malaria is oral artemether-lumefantrine and for 
severe knowlesi malaria, intravenous artesunate.
Our study has several limitations. The main ones are 
the retrospective design and inability to review 10% of the 
charts. Although samples from most P. malariae patients 
were sent for molecular conﬁ  rmation, 8% of the results 
were unavailable. Several cases microscopically diagnosed 
as falciparum or vivax malaria were PCR-positive for P. 
knowlesi. Because only ≈15% of non–P. malariae slides 
are sent for PCR, we may have underestimated the true 
proportion of patients hospitalized with knowlesi malaria. 
Because QEH is a hospital for adults, we were unable to 
describe the disease spectrum in children.
Our study further highlights the public health 
implications of P. knowlesi. A high proportion of knowlesi 
malaria patients admitted to a tertiary care referral hospital 
in a malaria-endemic area had severe and fatal disease 
characterized by multiorgan failure, a high proportion 
with ARDS and shock, and a notable absence of coma. 
The pathogenic mechanisms underlying this disease 
spectrum remain unknown. Artemisinin derivatives result 
in rapid parasite clearance and are efﬁ   cacious in both 
uncomplicated and severe knowlesi malaria. Prospective 
studies to further deﬁ  ne the epidemiology, pathogenesis, 
and optimal treatment for knowlesi malaria are needed.
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